A pilot study on a combined non-invasive screening test for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes
Combining a <sup>13</sup>C-methionine BT with an OGTT significantly impacts <sup>13</sup>C-methionine kinetics, but not OGTT results. A potential mechanism includes a glucose-induced delay of gastric emptying. Combined testing may be feasible when time-adjusted measurements are used, potentially allowing simultaneous screening for both T2D and MASLD-associated mitochondrial dysfunction in clinical practice.
Authors
- Wolfgang Schmid (ORCID: https://orcid.org/0000-0001-6191-2781)
- Alanna Ebigbo (ORCID: https://orcid.org/0000-0001-7765-035X)
- Oscar Cahyadi (ORCID: https://orcid.org/0000-0002-5624-9935)
- Daniel Robert Quast (ORCID: https://orcid.org/0000-0003-4357-6846)
- Christian Torres Reyes
- Katrin Saenger
Institutions
- St. Josef-Hospital (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.3389/fendo.2026.1780005
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00